Publication | Closed Access

Gemcitabine + vinorelbine (GV) yields better survival than vinorelbine (V) alone in elderly non-small cell lung cancer (NSCLC) patients. Final analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial

OncologyCancer ManagementMetronomic TherapyPharmacologyClinical TrialsPhase Iii TrialPharmacotherapyCancer TreatmentMedicineLung CancerBetter SurvivalFinal Analysis